Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
Sierra Oncology LLC - a GSK company
Srdan Verstovsek; Aaron T Gerds; Alessandro M Vannucchi; Haifa Kathrin Al-Ali; David Lavie; Andrew T Kuykendall; Sebastian Grosicki; Alessandra Iurlo; Yeow Tee Goh; Mihaela C Lazaroiu; Miklos Egyed; Maria Laura Fox; Donal McLornan; Andrew Perkins; Sung-Soo Yoon; Vikas Gupta; Jean-Jacques Kiladjian; Nikki Granacher; Sung-Eun Lee; Luminita Ocroteala; Francesco Passamonti; Claire N Harrison; Barbara J Klencke; Sunhee Ro; Rafe Donahue; Jun Kawashima; Ruben Mesa; MOMENTUM Study Investigators